Experience as Deputy CEO & CFO at XO CARE, a leading dental unit manufacturer, with overall responsibility for finance, HR, IT, legal, operations and quality:• Leading the finance department, optimizing finance processes, accounting, reporting, cash flow management, budgeting, and forecasting for enhanced efficiency and transparency.• Implementing cost control measures and driving operational improvement initiatives to maximize company profitability.• Developing and executing the corporate strategy, acting as a strategic partner to the CEO.• Supporting commercial growth initiatives to drive revenue.• Ensuring a modern and up-to-date IT infrastructure, driving the migration and implementation of a new ERP system and business intelligence tools.• Managing HR operations, ensuring compliance with policies and regulations.• Overseeing operations and quality.XO CARE is a 70-year-old family-owned, leading dental equipment manufacturer, specializing in dental units. The company is widely recognized for its commitment to high quality, ergonomic design, and innovative dental solutions. XO CARE's operations cover the entire value chain, including the development, production, marketing, and sales of dental units and instruments from its headquarters in Hørsholm, Denmark. XO CARE employs a network of sales and service partners across Europe and beyond.

Member of the Board of Directors.DCR Solutions helps organizations in heavily regulated industries such as the public, healthcare, and finance sector to instantly digitize their processes ensuring higher compliance and transparency, while saving employees time and company costs.How? By providing a cloud-based no-code SaaS solution, a new approach to process digitalization and process mining that guarantees automatic compliance. DCR Solutions fully digitises and continuously improves complex real-life processes.

Experience as Chief Financial Officer (CFO) in a publicly-traded MedTech company reporting directly to the CEO and Board of Directors with responsibility for corporate strategy, finance, investor relations, and commercial excellence projects:• Led the finance department by improving financial accounting and reporting (internal and external) and optimizing strategic financial management, including sourcing financing, cash flow management, budgeting, and forecasting.• Handled investor relations in collaboration with the CEO by providing relevant information to investors in a timely and accurate way (e.g., company announcements, quarterly and annual reports, investor conferences, earnings calls, and Annual General Meeting).• Drove corporate strategy through co-creation, implementation, and tracking of strategic growth initiatives and operational improvement initiatives.• Supported sales and marketing by driving commercial excellence projects (covering offering, positioning, and go-to-market model).• Led strategic digitalization projects across the organization (e.g., automated reporting and upgrade of ERP, CRM, and marketing tools).• Oversaw risk management and compliance, ensuring adherence to regulations such as MAR and other applicable regulations.ViroGates is an international NASDAQ First North Growth Market listed MedTech company developing and marketing prognostics products to the healthcare sector. Based on more than 800 clinical trials and studies, ViroGates’ suPARnostic® products supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics, Siemens Healthineers and Abbott instruments. ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark.

Experience as a senior management consultant in Bain & Company (QVARTZ) with strategy, commercial excellence and M&A projects in a variety of industries, including private equity, software, industry, pharma, transport & logistics, public, FMCG, media and financial services.Project examples:• Corporate strategy for a large Nordic industrial company• Corporate strategy for a large wholesale conglomerate• Several commercial due diligences on large European private equity deals• Digital transformation concept with a Fortune 500 global leader within digital solutions• E-commerce strategy implementation in a global consumer goods company• Commercial excellence in two leading Danish financial institutions• Commercial excellence in a global consumer electronics manufacturer• Operational excellence in a leading Nordic software company• Operational excellence/supply chain optimization in a global consumer goods company• Innovation strategy and process for a global consumer goods company• Organization/commercial excellence in a global pharmaceutical company• Internet of Things (IoT) platform requirements for global industrial company• Risk management in one of Europe's largest construction projects• Market expansion for a leading media company• Strategic cost optimisation in the Danish public sectorQVARTZ was acquired by Bain & Company in 2019 and was a large first-tier management consulting company in the Nordics.

Led a group marketing team working across ventures as an expatriate in the Philippines reporting directly to Managing Partners Mads Faurholt-Jørgensen and Stefan Bruun:• Hired, trained and retained a full business unit from 0 to +30 people.• Developed an agile, fail-fast, trust-based organization with streamlined processes and tools, clear roles and responsibilities, and transparent performance metrics.• Consistently delivered double-digit monthly growth for all ventures in +10 countries, including for a venture that later raised a 40 USDm Series A led by Goldman Sachs.

Estimated market attractiveness, mapped market dynamics and identified market trends in New Business Development (3 months). Supported the strategic business planning process in the Strategy Execution Office and Technical Industries (7 months).Novozymes is a global biotechnology company focusing on research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company holds an estimated 48% of the global enzyme market, making it the world’s largest producer of industrial enzymes.